Spero Therapeutics Inc. (SPRO) exhibits 45.0% gross margins and 26.6% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 5.1x enterprise multiple and 4.8% implied options volatility.
Sustained 45.0% gross profitability converts into 50.2% operating margin and 26.6% ROIC, outpacing sector cost of capital.
ROIC: 26.6% // GM: 45.0%YoY revenue trajectory of +180.0% paired with -19.53% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +180.0% // FCF YLD: -19.53%Altman Z-Score of 0.20 and Piotroski F-Score of 5/9 indicate low near-term refinancing stress.
ALTMAN Z: 0.20 // F-SCORE: 5/9Trading at 7.5x trailing P/E (6.3x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 7.5x // EV/EBITDA: 5.1xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $1.06 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 68.0% net margins.
NET MARGIN: 68.0% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for SPRO & activate live FRED threshold breach alerts.